State of the art investigations of immune responses related to human infectious diseases, autoimmune diseases, organ and cell allogeneic and xenogeneic transplantation models or immunization procedures that use NHP models increasingly include the use of recombinant cytokines, chemokines or immunomodulatory receptors in vivo. The close evolutionary relationship between human and NHPs provide adequate cross reactivity between human recombinant factors with NHP cells, albeit differences in affinity/bioactivity have been noted. However, most, if not all NHP determinants are not identical to human factors, often leading to a more or less rapid development of neutralizing antibody responses to the xenogeneic factor in vivo, potentially leading to data that are difficult to interpret. The practical consequence of this issue is the restriction of the use of such factors to single or short-term treatment whereas most such """"""""natural"""""""" immunomodulators work optimally only when administered in low but repeated doses. Clearly, availability of well-characterized and standardized purified NHP specific recombinant factors would alleviate this serious caveat. Among NIH investigators, a """"""""CRISP"""""""" search identified >30 proposals that would directly benefit from such reagents. Letters of support from 25 investigators are supplied with this application. In this application, it is proposed to develop a resource for providing NHP cytokines/chemokines/soluble co-stimulatory factors, DNA constructs capable of expressing such factors and explore strategies for improving the pharmacokinetics and biological effects of such reagents in vivo. The applicants submit that this resource will greatly enhance the validity of studies using such factors in a variety of NHP models of human disease, including but not restricted to candidate vaccines against infectious disease. Specifically, the applicant will establish a resource for: 1) Preparation, testing and distribution of nonhuman recombinant cytokines/chemokines and soluble factors. 2) Construction and testing of optimized plasmid based constructs for the expression of NHP cytokines/chemokines and immunomodulatory factors. 3) Development and testing of """"""""primatized"""""""" NHP cytokine/chemokines and immunomodulatory factors with extended half-life and biological activity in vivo.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Resource-Related Research Projects (R24)
Project #
1R24RR016988-01
Application #
6450929
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Program Officer
Robinson, Jerry
Project Start
2002-04-01
Project End
2006-03-31
Budget Start
2002-04-01
Budget End
2003-03-31
Support Year
1
Fiscal Year
2002
Total Cost
$304,000
Indirect Cost
Name
Emory University
Department
Pathology
Type
Schools of Medicine
DUNS #
042250712
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Ryan, Emily S; Micci, Luca; Fromentin, RĂ©mi et al. (2016) Loss of Function of Intestinal IL-17 and IL-22 Producing Cells Contributes to Inflammation and Viral Persistence in SIV-Infected Rhesus Macaques. PLoS Pathog 12:e1005412
Hong, Jung Joo; Amancha, Praveen K; Rogers, Kenneth A et al. (2014) Early lymphoid responses and germinal center formation correlate with lower viral load set points and better prognosis of simian immunodeficiency virus infection. J Immunol 193:797-806
Hong, Jung Joo; Amancha, Praveen K; Rogers, Kenneth et al. (2012) Spatial alterations between CD4(+) T follicular helper, B, and CD8(+) T cells during simian immunodeficiency virus infection: T/B cell homeostasis, activation, and potential mechanism for viral escape. J Immunol 188:3247-56
Lugli, Enrico; Mueller, Yvonne M; Lewis, Mark G et al. (2011) IL-15 delays suppression and fails to promote immune reconstitution in virally suppressed chronically SIV-infected macaques. Blood 118:2520-9
Pallikkuth, Suresh; Rogers, Kenneth; Villinger, Francois et al. (2011) Interleukin-21 administration to rhesus macaques chronically infected with simian immunodeficiency virus increases cytotoxic effector molecules in T cells and NK cells and enhances B cell function without increasing immune activation or viral replication. Vaccine 29:9229-38
Dubie, Robert A; Maksaereekul, Saipiroon; Shacklett, Barbara L et al. (2009) Co-immunization with IL-15 enhances cellular immune responses induced by a vif-deleted simian immunodeficiency virus proviral DNA vaccine and confers partial protection against vaginal challenge with SIVmac251. Virology 386:109-21
Klatt, Nichole R; Villinger, Francois; Bostik, Pavel et al. (2008) Availability of activated CD4+ T cells dictates the level of viremia in naturally SIV-infected sooty mangabeys. J Clin Invest 118:2039-49
Pereira, L E; Villinger, F; Wulff, H et al. (2007) Pharmacokinetics, toxicity, and functional studies of the selective Kv1.3 channel blocker 5-(4-phenoxybutoxy)psoralen in rhesus macaques. Exp Biol Med (Maywood) 232:1338-54
Ansari, Aftab A; Pereira, Lara E; Mayne, Ann E et al. (2007) The role of disease stage, plasma viral load and regulatory T cells (Tregs) on autoantibody production in SIV-infected non-human primates. J Autoimmun 28:152-9
Onlamoon, Nattawat; Plagman, Nicholas; Rogers, Kenneth A et al. (2007) Anti-CD3/28 mediated expansion of macaque CD4+ T cells is polyclonal and provides extended survival after adoptive transfer. J Med Primatol 36:206-18

Showing the most recent 10 out of 16 publications